Akeso announces NMPA acceptance of second NDA for gumokimab

Akeso (AKESF) announced that its supplemental New Drug Application, sNDA, for gumokimab, AK111, has been accepted for review by the Center for Drug Evaluation, CDE, of the National Medical Products Administration, NMPA. Active ankylosing spondylitis is the second indication for which gumokimab has gained acceptance for NDA review. The application for its use in treating moderate-to-severe psoriasis was previously accepted by the CDE in January 2025.